• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Medtronic wins Supreme Court ruling in patent row with Boston Scientific

Medtronic wins Supreme Court ruling in patent row with Boston Scientific

January 22, 2014 By Arezu Sarvestani

Medtronic wins Supreme Court ruling in patent row with Boston Scientific

Medtronic‘s (NYSE:MDT) notched a major win today with a unanimous Supreme Court ruling in its favor that it does not bear the burden of proof in a long-standing patent war with rival Boston Scientific (NYSE:BSX), which holds exclusive licensing rights to fundamental cardiac rhythm therapy patents owned by Mirowski Family Ventures.

The court ruled this week that MFV must prove that Medtronic’s devices are in violation even though Medtronic filed the original challenge against the patent in 2003, while still under a sub-license agreement for the technology.

Since Medtronic brought the initial lawsuit while still under the licensing agreement, it created a unique situation that raised questions about who was the plaintiff and who was the defendant in the case.

"Simple legal logic, resting upon settled case law, strongly supports our conclusion," Supreme Court Justice Stephen Breyer wrote in the ruling. "It is well established that the burden of proving infringement generally rests upon the patentee."

Deciding otherwise would leave too much ambiguity in the patent system, Breyer added. He imagined a scenario in which Medtronic could be found guilty of infringement if it was unable to prove otherwise, and yet a company engaged in the same behavior could be found not guilty of infringement because Boston Scientific would still bear the burden of proof in standard patent lawsuits.

"Both sides might lose as to infringement, leaving the infringement question undecided, creating uncertainty among the parties and others who seek to know just what products and processes they are free to use," Breyer wrote. "General considerations relating to the public interest in maintaining a well-functioning patent system are, at most, in balance, and do not favor changing the ordinary burden of proof rule."

Medtronic tallied a win today, but the lawsuit isn’t over.

"We are very pleased with the Court’s unanimous ruling, which affirmed in this case there is no reason burden of proof law should favor the patentee," Medtronic vice president and acting general counsel Neill Ayotte said in prepared remarks. "The case will now be remanded back to the Federal Circuit court for further review of other issues in the Mirowski appeal."

History

The long-running dispute concerns fundamental CRT technology covered patents issued to CRM pioneer Dr. Morton Mower, credited with inventing the technology that ultimately became known as a cardiac resynchronization therapy device. Family Ventures owns 2 of the CRT patents, which it exclusively licenses to Guidant Corp., which Boston Scientific acquired in 2006 for an eyebrow-raising $26 billion.

Medtronic in 1991 entered into a sub-license agreement for the patents with Eli Lilly (NYSE:LLY), which owned Guidant at the time. The agreement gave Medtronic leverage to challenge 1 of the patents, which the company began doing in 2003. Since then the various companies involved have been fighting over the validity of 1 of the MFV patents and over Medtronic’s alleged infringement, going round after round in a series of lower courts.

The lawsuit reached the Supreme Court as a debate over which party bears the burden of proof when a patentee, Boston Scientific, claims infringement by a licensee, Medtronic. 

Delaware District Court Judge Susan Robinson ruled in April 2011 that the burden rested on the patentee, and in September 2012 Federal Circuit Judges Richard Linn, Alan Lourie and Sharon Prost agreed, concluding that a lower court had mistakenly put the burden of proof on MFV when Medtronic had "disturbed the status quo" with its lawsuit.

In April 2013 the U.S. Solicitor General filed an amicus curiae brief that effectively backed Medtronic, arguing that a lower court ruled incorrectly that Medtronic bears the burden of proof in demonstrating that its products do not infringe on the patents in question. The patent holder should always bear that responsibility, according to the brief.

Repercussions

Legal analysts have warned that the Solicitor General may have failed to take into consideration the unique nature of the litigation and the precedents set by a 2007 Supreme Court decision in a lawsuit between MedImmune and Genentech. The court ruled in that case that a licensee can challenge the validity of a patent without canceling the licensing agreement, shifting to the licensee a significant amount of power during negotiations.

The Solicitor General argued in its brief that the lower courts that put the burden of proof on Medtronic forced the company, as the "alleged infringer," into a position of having to demonstrate that it does not violate any given patents. Medtronic would have to effectively "identify and negate every conceivable theory on which the product could infringe."

That may be an exaggeration as well as a misrepresentation of the somewhat unique nature of the case, according to attorney Andrew Williams, writing for Patent Docs.

"This is the 1st time since the enactment of the Declaratory Jurisdiction Act that an ‘accused infringer’ has had the burden of proving non-infringement," wrote Williams, who is a partner with McDonnell Boehnen Hulbert & Berghoff LLP. "But the use of the term ‘accused infringer’ in the brief highlights the appropriateness of this argument in this context – the declaratory-judgment plaintiff is a licensee, and therefore is not necessarily being accused of infringing.  Rather, the licensee has entered into an agreement by which it has a right to practice the patented technology. Therefore, even though it cannot be presumed that the declaratory-judgment plaintiff has conceded infringement because of the existence of a license, the fact that MedImmune creates a unique situation must be acknowledged."

Filed Under: Legal News, News Well, Patent Infringement Tagged With: Boston Scientific, Cardiac Rhythm Management, Minnesota, U.S. Supreme Court

In case you missed it

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Dyad Medical wins FDA clearance for cardiac imaging platform Echo:Prio
  • Outset Medical wins national VA contract
  • Inspire Medical Systems appoints former Zimmer Biomet exec as VP of investor relations
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Acutus Medical ticks up on revenue beat, missed EPS in Q2 results
  • ResMed expects steady growth over the next year
  • Ambu is letting go of 200 employees
  • Medtronic has Class I recall for low-shock risk in ICDs
  • Titan Medical to start manufacturing Enos systems later this year
  • ZimVie sales down more than 11% in Q2 as it streamlines after spinoff
  • Cardinal Health’s CFO to move up to corner office
  • Levita Magnetics raises $26M for Magnetic-Assisted Robotic Surgery platform
  • Data supports use of Channel Medsystems Cerene cryotherapy
  • The 10 largest orthopedic device companies in the world
  • Nanopath raises $10M Series A for women’s health diagnostics
  • Avenda wins FDA IDE nod for AI-enabled prostate cancer therapy

RSS From Medical Design & Outsourcing

  • TE Connectivity opens global medical device prototyping center in Ireland
    TE Connectivity (NYSE:TEL) today announced it opened its global Propelus Prototype Center for medical devices in Galway, Ireland. The $5 million rapid prototyping center was built into its existing manufacturing site in Galway and directly connects TE engineers with customers to reduce development time and increase speed to market for lifesaving and life-improving medical devices. Propelus… […]
  • Contract manufacturer Minnetronix Medical launches its first in-house product, MindsEye
    Minnetronix Medical has launched MindsEye, making it the first medical device that the contract developer and manufacturer has conceived and commercialized. St. Paul-based Minnetronix Medical’s MindsEye is the first expandable brain access port on the market. The FDA cleared the device under the 510(k) pathway in August 2020. The minimally invasive device gives neurosurgeons deep… […]
  • What’s next for Jennifer Fried after leaving Explorer Surgical?
    Explorer Surgical co-founder Jennifer Fried has resigned from the company after selling it to Global Healthcare Exchange in October. Fried announced her departure last week on LinkedIn, saying she’s preparing for her next professional chapter. “It’s bittersweet — I’m so proud of everything our team has built and accomplished,” Fried wrote. “The time has flown… […]
  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]
  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy